Author + information
- 1Beijing Anzhen Hospital, Capital Medical University, Beijing, China; Beijing Institute of Heart, Lung, and Blood Vessel Diseases, Beijing, China; The Key Laboratory of Remodeling-Related Cardiovascular Diseases, Ministry of Education, Beijing, China
- 2State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, Jiangsu, China
Metabolomics demonstrated powerful diagnostic and prognostic value in heart failure patients. However, it is unknown whether metabolic profiles provide a diagnostic value to discriminate heart failure based on different heart diseases.
A total of 75 adult patients with symptomatic heart failure underwent echocardiography and nuclear magnetic resonance to clarify the cause of heart failure. Metabolic profiles of dilated cardiomyopathy (DCM) patients and ischemic cardiomyopathy (ICM) patients were investigated. Serum metabolomic profiles were determined by liquid chromatography-quadrupole time-of-flight mass spectrometry using fasting serum samples. Principal components analysis and orthogonal partial least squares discriminant analysis model were used for data reduction.
In this single-center study, groups were divided as DCM (n=30) and ICM (n=30). Mean age of DCM patients was 53.9±9.4 years, and 20% were women, and mean age of ICM patients was 54.7±8.7 years, and 13% were women. A total of 2044 metabolites were identified, including 1275 positively charged metabolites and 769 negatively charged metabolites. However, there is no significant separation between DCM patients and ICM patients using an orthogonal partial least squares discriminant analysis model. With strong correlation of average metabolite levels in DCM patients and ICM patients, DCM patients had similar metabolite levels to DCM patients. Although combination of N-Acetyl-L-glutamine and 2,3-Pyridinedicarboxylic acid can weakly differentiate DCM patients and ICM patients with areas under the curves (AUC=0.53), but profile of metabolites could not provide better diagnostic value versus conventional imaging results.
In our metabolomics approach, metabolites we examined have poor diagnostic value to discriminate heart failure patients based on ischemic cardiomyopathy and dilated cardiomyopathy.